May 24 |
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
May 15 |
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
|
May 14 |
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
|
May 6 |
aTyr Pharma to Present at Upcoming Investor Conferences
|
May 2 |
aTyr Pharma GAAP EPS of -$0.23 beats by $0.02, revenue of $0.24M beats by $0.22M
|
May 2 |
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
|
Apr 21 |
aTyr Pharma Insiders Placed Bullish Bets Worth US$514.6k
|
Apr 1 |
aTyr Pharma to Participate in April Investor Conferences
|
Mar 26 |
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
|
Mar 16 |
aTyr Pharma Full Year 2023 Earnings: Revenues Disappoint
|